Glaxo pays $155M for Lunesta rights

GlaxoSmithKline will fork over up to $155 million to commercialize the sleep aid Lunesta outside of North America and Japan. Made by Sepracor, the drug will be sold under the brand name Lunivia; it's under regulatory review in Europe, and could get the go-ahead in up to 27 E.U. nations.

Lunesta has been a cash cow for Sepracor, delivering some $567 million in 2006 sales. The market for insomnia drugs in Europe is worth about $500 million--and that's with only 24 percent of insomniacs being treated. In other words, there's lots of upside on the continent.

- see the GlaxoSmithKline reelease
- read the Boston Business Journal report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.